KALL XI (92) - Acute lymphoblastic leukaemia trial

Not Applicable

Completed

• Conditions: Cancer; eukaemia; Acute lymphoblastic leukaemia

• Registration Number: ISRCTN16757172
• Lead Sponsor: Medical Research Council (MRC) (UK)

Brief Summary

2001 Protocol article in http://www.ncbi.nlm.nih.gov/pubmed/11328289 2002 Results article in http://www.ncbi.nlm.nih.gov/pubmed/11813173 2004 Results article in http://www.ncbi.nlm.nih.gov/pubmed/14675406 2011 Results article in https://pubmed.ncbi.nlm.nih.gov/21996369/ (added 01/09/2022)

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Completion: 1997-12-31
• Study Start: 2000-10-25
• Last Update Posted: 12 September 2022

Recruitment & Eligibility

• Status: Completed
• Sex: All
• Target Recruitment: 2090

Inclusion Criteria

They are children including those with Down's syndrome or leukaemia associated chromosome translocations over 1 year and under 15 years with newly diagnosed ALL of any immunologic subtype except B-A

Exclusion Criteria

Children with B-ALL and those under 1 year

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Disease-free survival, CNS disease eradication, relapse rates, psychometric test results.

Secondary Outcome Measures

Name	Time	Method
ot provided at time of registration